World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
79
Citations
28046
World Ranking
17418
National Ranking
8719

Branimir I. Sikic publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Branimir I. Sikic sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 348 publications — 27th percentile

27% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Branimir I. Sikic D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Branimir I. Sikic sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 79 D-Index — 14th percentile

14% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Branimir I. Sikic is affiliated with Stanford University in the United States and has contributed extensively to the fields of medicine and biochemistry, genetics, and molecular biology. Their research primarily focuses on oncology, with significant work in molecular biology, cell biology, pediatrics, perinatology, and genetics.

The main topics covered in their work include drug transport and resistance mechanisms, cancer immunotherapy and biomarkers, CAR-T cell therapy research, microtubule and mitosis dynamics, pharmacological effects and toxicity studies, hemoglobinopathies and related disorders, and acute myeloid leukemia research.

Among their recent papers are the following:

  • Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies, 2020, Blood Advances
  • Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors, 2022, Journal for ImmunoTherapy of Cancer
  • Carboplatin-induced upregulation of pan β-tubulin and class III β-tubulin is implicated in acquired resistance and cross-resistance of ovarian cancer, 2023, Cellular and Molecular Life Sciences
  • Drug Resistance and Its Clinical Circumvention, 2022, Holland-Frei Cancer Medicine
  • A Phase I Trial of the ABCB1 Inhibitor, Oral Valspodar, in Combination With Paclitaxel in Patients With Advanced Solid Tumors, 2023, American Journal of Clinical Oncology

Their frequent co-authors include:

  • George E. Durán
  • Thomas Hawthorne
  • Tracey Rawls
  • Tibor Keler
  • Michael Yellin

Branimir I. Sikic's work has been published in several journals and publication venues, including:

  • Cancer Chemotherapy and Pharmacology
  • Blood Advances
  • Journal for ImmunoTherapy of Cancer
  • Cellular and Molecular Life Sciences
  • American Journal of Clinical Oncology

Best Publications

  • Integrated genomic analyses of ovarian carcinoma

    D. Bell;A. Berchuck;M. Birrer;J. Chien

  • Mechanisms of Action of and Resistance to Antitubulin Agents: Microtubule Dynamics, Drug Transport, and Cell Death

    Charles Dumontet;Branimir I. Sikic

  • First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.

    Branimir I. Sikic;Nehal Lakhani;Amita Patnaik;Sumit A. Shah

  • Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity

    Jean-Pierre Marie;Robert Zittoun;Branimir I. Sikic

  • Methods to Detect P-Glycoprotein-associated Multidrug Resistance in Patients' Tumors: Consensus Recommendations

    William T. Beck;Thomas M. Grogan;Cheryl L. Willman;Carlos Cordon-Cardo

  • Gene Expression Patterns in Ovarian Carcinomas

    Marci E. Schaner;Douglas T. Ross;Giuseppe Ciaravino;Therese Sørlie

  • Detection of cell-affecting agents with a silicon biosensor

    JW Parce;JC Owicki;KM Kercso;GB Sigal

  • Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein

    B. I. Sikic;George A. Fisher;Bert L. Lum;Joanne Halsey

  • Functional Network Analysis Reveals Extended Gliomagenesis Pathway Maps and Three Novel MYC-Interacting Genes in Human Gliomas

    Markus Bredel;Claudia Bredel;Dejan Juric;Griffith R. Harsh

  • Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.

    Bert L. Lum;Sonia Kaubisch;Anne M. Yahanda;Kent M. Adler

  • Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995)

    Peter L. Greenberg;Sandra J. Lee;Ranjana Advani;Martin S. Tallman

  • NFKBIA Deletion in Glioblastomas

    Markus Bredel;Denise M. Scholtens;Ajay K. Yadav;Angel A. Alvarez

  • Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA.

    Harker Wg;Sikic Bi

  • Modulation of multidrug resistance: at the threshold.

    B I Sikic

  • Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance.

    A M Yahanda;K M Alder;G A Fisher;N A Brophy

  • Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion

    John J. Gullo;John J. Gullo;Charles L. Litterst;Patrick J. Maguire;Patrick J. Maguire;Branimir I. Sikic;Branimir I. Sikic

  • Gastrin releasing peptide is a selective mitogen for small cell lung carcinoma in vitro.

    S Weber;J E Zuckerman;D G Bostwick;K G Bensch

  • Molecular Pathways: Regulation and Therapeutic Implications of Multidrug Resistance

    Kevin G. Chen;Branimir I. Sikic

  • High-resolution genome-wide mapping of genetic alterations in human glial brain tumors.

    Markus Bredel;Claudia Bredel;Claudia Bredel;Dejan Juric;Griffith R. Harsh

  • Integrated genomic analyses of ovarian carcinoma

    D. Bell;A. Berchuck;M. Birrer;J. Chien

Frequent Co-Authors

Heather A. Wakelee
Heather A. Wakelee Stanford University
Ranjana H. Advani
Ranjana H. Advani Stanford University
Hannes Vogel
Hannes Vogel Stanford University
Robert Tibshirani
Robert Tibshirani Stanford University
Nelson J. Chao
Nelson J. Chao Duke University
Howard J. Weinstein
Howard J. Weinstein Harvard University
Susana C. Raimondi
Susana C. Raimondi St. Jude Children's Research Hospital
Tibor Keler
Tibor Keler Bristol-Myers Squibb (United States)
Irving L. Weissman
Irving L. Weissman Stanford University
Amita Patnaik
Amita Patnaik University of Chicago

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring health careers beyond medical school can open a wide range of opportunities in the healthcare sector. For those passionate about patient care but seeking an alternative pathway, becoming a registered nurse is a popular choice. There are nursing school that doesn't require teas or HESI exams, making entry into the field more accessible.

If you are interested in leadership or administrative roles in healthcare, pursuing an accelerated healthcare administration degree can fast-track your career, allowing you to manage hospitals, clinics, or health organizations.

RNs looking to advance their education and clinical expertise can consider dedicated rn to np bridge programs to transition into nurse practitioner roles. These programs are designed for working professionals and streamline the journey from ADN to MSN.

Lastly, nutrition is a fast-growing area in healthcare. Accredited nutrition degrees online let students learn about dietetics, health promotion, and wellness—skills that are in high demand in hospitals, public health, and private practice.

Best Scientists Citing Branimir I. Sikic

Trending Scientists

Recently Published Articles